Helsinki, 20 July 2015 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, draws attention to the publication of abstracts from the 6th International Symposium on Navigated Brain Stimulation in Neurosurgery.
At the symposium, previously unpublished data was presented on the use of [Nexstim’s] Navigated Brain Stimulation (NBS) mapping in neurosurgery and neurosurgical planning, showing that the value of NBS to neurosurgery outcomes and workflows continues to support the wider adoption of the technology. The symposium heard of the positive outcome of Nexstim’s Phase II trial for navigated Transcranial Magnetic Stimulation (TMS) as an adjunctive treatment to physiotherapy in stroke rehabilitation in which 84% showed clinically important improvement, as well as the latest clinical research into the use of NBS as a therapy in tinnitus and pain control.
Nexstim’s NBS System is the first and only FDA-cleared and CE-marked navigated TMS device for pre-surgical mapping of the motor and speech cortices.
The abstracts can be accessed on Nexstim’s website: www.nexstim.com/healthcare-providers/navigated-brain-stimulation/clinical-evidence/nbs-symposium
Janne Huhtala, Chief Executive of Nexstim, commented: “Nexstim continues to lead developments in NBS and we’re pleased to maintain our close relationship with some of the world’s leading neurosurgeons, neurologists and departments. We look forward to further building these relationships with rehabilitation centres as we near the interim analysis from our multicentre Phase III stroke study in the US.”
Janne Huhtala, CEO